Statement of Principles concerning acute rheumatic fever (Reasonable Hypothesis) (No. 53 of 2019)

The SoP arranges a small number of tightly defined legal and medical concepts. These are explicit in the instrument and determine how the instrument is applied in the claims context.

Acute rheumatic fever. The operative medical definition is in s 7(2). Acute rheumatic fever is defined as a systemic inflammatory autoimmune disease that follows laboratory confirmed infection with beta‑haemolytic streptococcus. The instrument expressly excludes post‑streptococcal reactive arthritis (s 7(2)(b)). The notes to s 7 expand the clinical manifestations that may be included such as clinical or subclinical carditis, various joint presentations, central nervous system involvement, Sydenham chorea or indolent subclinical carditis, and they identify acceptable forms of laboratory confirmation (Note 1 and Note 2). Although ICD‑10‑AM codes I00, I01 or I02 are associated with acute rheumatic fever, the instrument makes clear that the statutory definition is the text in s 7(2) rather than solely the ICD code list (s 7(3)-(4)).

Death from acute rheumatic fever. The instrument treats death as included where the terminal event or condition was contributed to by the person’s acute rheumatic fever (s 7(5)). Schedule 1 defines terminal event to include proximate or ultimate causes such as pneumonia, respiratory failure, cardiac arrest, circulatory failure or cessation of brain function (Schedule 1).

Factors that must exist. Section 9 sets a closed list of factors; at least one must exist to raise the reasonable hypothesis. The list covers microbiological events (group A, C or G streptococcal infections with specified time windows), social and environmental exposures (crowded living or working conditions within one year), dental disease (dental caries within one year), and access to care (inability to obtain appropriate clinical management) (s 9).

Relationship to service and timing constraints. Section 10 requires that any factor relied upon be related to the person’s relevant service. The SoP defines relevant service in Schedule 1 to cover various VEA and MRCA service categories (operational, peacekeeping, hazardous, British nuclear test defence service, warlike, non‑warlike) (Schedule 1). Subsection 10(2) limits the application of the inability to obtain appropriate clinical management factor to situations where acute rheumatic fever was suffered or contracted before or during, but did not arise out of, the person’s relevant service.

Interaction with other Statements of Principles. Section 11 provides that where a factor in s 9 refers to an injury or disease already covered by another SoP under s 196B(2) of the VEA, the factors in that other SoP apply according to their terms as in force from time to time.

Authority and evidential posture. The instrument is an RMA determination under s 196B(2) of the VEA (s 3), and s 8 records the RMA’s view that sound medical‑scientific evidence supports the links set out in the SoP. The operative legal effect when this SoP is applied in VEA or MRCA claims is that the listed factors and definitions operate as the criteria for raising a reasonable hypothesis connecting the disease or death to relevant service. The instrument is not a statute imposing obligations outside the claims context; rather it sets the medical/causal thresholds that decision makers must apply when considering claims under the specified provisions of the VEA and MRCA (s 5).

The instrument affects a defined and narrow population. By its terms it applies to persons making claims under the VEA or MRCA where section 120A of the VEA or section 338 of the MRCA applies (s 5). That group will typically be veterans, members of Peacekeeping Forces, and members of the Forces as those terms are used in the VEA and MRCA. Schedule 1 defines “relevant service” to include operational, peacekeeping, hazardous and British nuclear test defence service under the VEA and warlike and non‑warlike service under the MRCA. Therefore the instrument affects:

• claimants who assert acute rheumatic fever or death from acute rheumatic fever in claims under the specified points of the VEA or MRCA; and
• decision makers and medical assessors who must apply the SoP when determining whether a reasonable hypothesis has been raised connecting the condition to relevant service.

Individuals outside the claims framework are not directly regulated by the instrument. The SoP is a decision‑support and legal threshold device to be used in the statutory claims processes. The RMA itself asserts that its view is founded on sound medical‑scientific evidence that acute rheumatic fever and death from it can be related to relevant service (s 8); that assertion affects the evidentiary posture of claims but does not on its face impose obligations on private parties beyond the claims setting.

The instrument also affects parties who will be asked to provide evidence in claims. Relevant documentation and sources of proof include laboratory confirmation of streptococcal infection (positive throat culture, rapid antigen test, molecular assay, or later positive serology as set out in s 7 Note 2), clinical records showing the timing of onset, dental records for dental caries, records or testimony about living or working conditions within the relevant year, and clinical records or administrative evidence of inability to obtain appropriate clinical management (s 7 Note 2; s 9(4)-(6)). For death claims, death certificates and records identifying terminal events as defined in Schedule 1 will be directly relevant (s 7(5); Schedule 1).

By requiring that the factor relied upon be related to the person’s relevant service (s 10(1)), the instrument places a nexus requirement between service and the listed factor. For s 9(6) in particular, the instrument narrows its application by limiting it to situations where the acute rheumatic fever was suffered or contracted before or during, but did not arise out of, the relevant service (s 10(2)).

Finally, the instrument affects other SoPs insofar as it cross‑references them. Where a factor in s 9 refers to an injury or disease covered by another SoP, the terms of that other SoP apply as they are in force (s 11). That means claim preparation and adjudication must track potentially multiple SoPs where factors intersect.

The Statement of Principles is not phrased as imposing duties on private persons in the sense of criminal or civil obligations. Rather, it sets legal thresholds and definitions that operate within the statutory claims framework under the VEA and the MRCA. The principal operational duties and rights that follow from the instrument are those of claimants and decision makers in the claims process.

Duties of claimants and their advisers. Although the instrument does not use the language of burdens, it creates practical duties for claimants who seek a finding that acute rheumatic fever or death from it is related to relevant service. A claimant must establish that at least one of the factors in s 9 exists, and that the factor is related to that person’s relevant service (s 9; s 10(1)). The claimant must therefore collect and rely on evidence capable of establishing one of the factors within its prescribed time window, for example:

• laboratory evidence of group A, C or G streptococcal infection within the specified months before clinical onset (s 9(1)-(3); s 7 Note 2);
• documentation of crowded living or working conditions within one year before clinical onset (s 9(4));
• dental records showing dental caries within one year before clinical onset (s 9(5)); or
• records evidencing inability to obtain appropriate clinical management where applicable, noting the limitation in s 10(2) for this factor (s 9(6); s 10(2)).

Rights of claimants. The SoP determines the medical criteria for raising a reasonable hypothesis connecting condition to service. If the claimant satisfies the SoP threshold by proving a listed factor related to relevant service, that will be a material step towards establishing entitlement under the VEA or MRCA processes where the SoP is engaged. The SoP does not itself grant a benefit; it sets a standard that decision makers must apply when assessing causation in claims.

Duties of decision makers and medical assessors. The RMA has issued the SoP under its statutory power (s 3) and has stated its view about the medical‑scientific foundation (s 8). Decision makers who apply the SoP in claims under s 120A of the VEA or s 338 of the MRCA must determine whether a reasonable hypothesis has been raised by the existence of at least one of the factors in s 9 and its relation to relevant service (s 9; s 10). Where a factor in s 9 refers to a condition covered by another SoP, decision makers must apply that other SoP’s factors as they are in force (s 11). The instrument therefore governs the evaluative framework of the decision maker rather than imposing independent regulatory obligations outside the claims framework.

Administrative rights. The instrument does not enumerate procedural rights such as review or appeal; those will be governed by the VEA, MRCA and their associated procedural regimes. The SoP’s role is evidentiary and definitional within those existing statutory procedures. Practitioners should therefore treat the SoP as setting the causation criteria to be applied in the statutory decision process, not as a source of standalone procedural entitlements.

The Statement of Principles contains no penalties, criminal offences, or administrative fines. It is a specialist, technical instrument that sets causation and evidentiary criteria to be used in the adjudication of claims under the VEA and MRCA. The instrument does not itself provide enforcement mechanisms in the sense of sanctions for non‑compliance. Its operative enforcement is indirect and occurs through the application of the SoP by decision makers in the statutory claims process.

How the SoP is operationalised in enforcement terms. The SoP applies to claims to which s 120A of the VEA or s 338 of the MRCA applies (s 5). Those statutes and their decision mechanisms, not the SoP text, prescribe decision‑making pathways, entitlements and review rights. Therefore the practical “enforcement” of the SoP is that decision makers will accept or reject a claim, or particular causal contentions in a claim, on the basis of whether the SoP criteria are met. If a claimant cannot establish that at least one factor in s 9 exists and is related to relevant service as required by s 10(1), the SoP will not provide a basis for concluding a reasonable hypothesis is raised, and the claim will be determined under the governing statutory provisions accordingly.

Role of the Repatriation Medical Authority. The RMA is the body that made the SoP under s 196B(2) of the VEA (s 3). The instrument records the RMA’s view that there is sound medical‑scientific evidence linking acute rheumatic fever and death from it to relevant service (s 8). The RMA’s function with respect to the SoP is to set the medical criteria. Application and enforcement of those criteria in the context of individual entitlements will be undertaken by the decision makers identified in the VEA and MRCA decision frameworks.

Limitations as to penalties. Because the instrument is a statement of principles, it does not itself create civil or criminal liabilities, nor does it prescribe sanctions for failing to adhere to a specified management practice for acute rheumatic fever. Any penalties or adverse consequences for failing to provide particular documents, or for false statements in a claim, are determined by the procedural and statutory provisions of the underlying Acts and not by this SoP.

Evidence and probative effect. The SoP’s function is to provide the diagnostic and temporal criteria for raising a reasonable hypothesis. It will therefore be used as the evidentiary benchmark in claims. The instrument’s lack of internal enforcement provisions means that compliance is realised through how decision makers apply the factors, including whether the decision maker accepts the laboratory, clinical or social evidence offered to establish a factor listed in s 9 and its connection to relevant service under s 10.

The Statement of Principles is explicitly framed to operate within the statutory frameworks of the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. The instrument is made under subsection 196B(2) of the VEA (s 3), and it applies to claims to which s 120A of the VEA or s 338 of the MRCA applies (s 5). Thus its legal effect is activated inside the claims processes those Acts define.

Interaction with the VEA and MRCA. The SoP provides the medical and causal criteria for adjudicating claims under particular sections of the VEA and MRCA. It does not amend or replace the operative entitlements, liabilities or review rights contained in those Acts. Decision makers applying the VEA or MRCA must use the SoP's factors and definitions when determining whether the requisite causal link or reasonable hypothesis exists for acute rheumatic fever or death from it. The instrument therefore functions as an evidentiary adjunct to the statutory test in those Acts.

Interaction with other Statements of Principles. Section 11 governs cross‑SoP interaction. If a factor in s 9 refers to an injury or disease that is the subject of another SoP determined under s 196B(2) of the VEA, then the factors in that other SoP apply “in accordance with the terms of that Statement of Principles as in force from time to time” (s 11). This creates a hierarchical or cross‑referential mechanism: when a s 9 factor implicates a separately regulated injury or disease, practitioners and decision makers must consult and apply the current terms of the other SoP. That means claims may engage multiple SoPs; the operative factors for any cross‑referenced condition will be those of the separate SoP as amended from time to time.

ICD‑10‑AM coding. The instrument notes that acute rheumatic fever attracts ICD‑10‑AM codes I00, I01 or I02, but states that in applying the SoP the meaning of acute rheumatic fever is that provided in s 7(2) rather than simply these codes (s 7(3)). The instrument also specifies which edition and publication of ICD‑10‑AM is referenced when a code is invoked (s 7(4)). Practically this means that clinical codings may be used as supporting material, but the statutory definition is textual and tied to laboratory confirmation and clinical presentation as specified in s 7(2) and its notes.

Evidence law and administrative procedure. The SoP does not alter general evidentiary rules or administrative law procedures under the VEA and MRCA. It supplies a medical standard to be applied by decision makers working under the statutory processes. Any evidentiary or procedural consequences beyond the SoP itself (for example, rules governing admissibility of records, procedural fairness, review rights, or remedies) remain governed by the relevant provisions of the VEA, MRCA and associated regulations and case law; the SoP interacts with those laws by defining the specific medical criteria decision makers must test against.

Repeal of prior SoP. Section 4 repeals the earlier SoP No. 23 of 2011. That repeal means that, from commencement on 27 May 2019, the 2019 SoP is the operative RMA determination for acute rheumatic fever matters within the relevant statutory claims contexts. Any transitional or retrospective application issues would be governed by the VEA/MRCA and by standard administrative practice, not by the SoP text itself.

This instrument sets out its own immediate amendment history in two limited respects. It makes plain when it commenced and that it repealed the prior Statement of Principles relating to acute rheumatic fever.

Commencement. The instrument commenced on 27 May 2019 (s 2). That is the operative date from which the instrument’s definitions and factors are to be used in the applicable claims processes under the VEA and MRCA (s 5).

Repeal of prior Statement of Principles. Section 4 repeals the Statement of Principles concerning acute rheumatic fever No. 23 of 2011 (Federal Register of Legislation No. F2011L00503) made under subsection 196B(2) of the VEA. The effect of that repeal is that the 2011 instrument ceased to be the operative RMA determination on commencement of this 2019 instrument. The text does not provide transitional provisions or savings clauses; therefore application to claims will follow the commencement and repeal sequencing set out in s 2 and s 4. Any consequences for claims spanning the repeal would be governed by the statutory decision rules in the VEA and MRCA and by administrative practice.

No other amendments recorded in this instrument. The instrument does not record prior amendments to itself, nor does it amend other legislative instruments or Acts. It redescribes the condition, updates definitions and factors, and replaces the previous 2011 SoP. Any further amendments to the SoP after the date of this instrument are not contained in the text and would be documented in subsequent RMA determinations or legislative instruments.

Edition reference for ICD coding. The instrument references a specific edition and effective date of the ICD‑10‑AM for the purposes of code citations (s 7(4)). That is a fixed technical reference included in the instrument and functions as a form of cross‑reference rather than an amendment mechanism. If future editions of ICD‑10‑AM are published, the instrument does not itself update to refer to them; for the purposes of this instrument the edition stated applies.

Schedule and definitions. The Schedule 1 dictionary is part of the instrument and supplies definitions such as MRCA, VEA, relevant service and terminal event. Any future amendment to these defined terms would require an amending instrument by the RMA under the enabling subsection 196B(2) of the VEA or legislative amendment in the underlying Acts.

The Statement of Principles instrument itself does not record any litigation decisions, cases or judicial determinations. The instrument does not cite or rely upon any judicial authorities by name. It is a technical determination of the Repatriation Medical Authority made under subsection 196B(2) of the VEA (s 3), and the text contains no references to litigation outcomes, case names or judicial interpretations.

The instrument does record internal administrative history, notably the repeal of the 2011 SoP (s 4), but it does not contain any description of challenges to that prior instrument or of judicial review proceedings. It also records the RMA’s view that sound medical‑scientific evidence supports the causal links set out in the SoP (s 8), but that is an administrative finding and not a judicial determination.

For practitioners preparing claims or appeals, the relevant litigation history will be found in decisions under the VEA and MRCA that apply the SoP. Those cases are not included inside this instrument. The SoP does provide the criteria decision makers must apply when assessing whether a reasonable hypothesis has been raised. Any litigation concerning the application or interpretation of this SoP would therefore turn on the statutory framework of the VEA and MRCA and on the factual application of the factors in s 9 and the nexus requirement in s 10. The instrument itself does not contain or report such litigation.

Because the instrument cross‑references other Statements of Principles (s 11), litigation that has considered interactions between SoPs may be relevant in practice, but no such litigation is identified in the SoP. Where s 9 refers to an injury or disease covered by another SoP, the factors of that other SoP apply as in force from time to time; any judicial interpretation of those other SoPs would be discovered in the case law relevant to those instruments, not in this instrument.

This SoP contains a number of technical features and limitations that can catch claimants and advisers if they are not carefully navigated. The instrument’s text is short but precise, and the consequences for admissible evidence and causation assessments turn on its definitions, temporal windows, nexus requirement and cross‑references.

1. The operative definition is textual, not code‑bound. Section 7(3) clarifies that although acute rheumatic fever attracts ICD‑10‑AM codes I00, I01 or I02, the meaning to be applied for the SoP is the textual definition in s 7(2). Practitioners should not rely on ICD codes alone. The instrument also specifies the edition and publication for ICD‑10‑AM code references (s 7(4)). The practical consequence is that coded entries on healthcare records are useful but insufficient; the clinical and laboratory criteria set out in s 7(2) and Note 2 are determinative.

2. Laboratory confirmation is expressly required in the definition. The statutory definition in s 7(2)(a) describes acute rheumatic fever as following laboratory confirmed infection with beta‑haemolytic streptococcus. Note 2 enumerates acceptable methods of laboratory confirmation including throat culture, rapid antigen test, molecular assay, or positive serology later. If a claimant lacks those forms of laboratory evidence, it will be more difficult to satisfy the SoP’s definitional criterion.

3. Time windows vary by factor and by clinical presentation. Section 9 provides different temporal limits depending on the factor and the clinical form of acute rheumatic fever. Group A streptococcal infection of skin or pharynx must be within three months of clinical onset (s 9(1)). For isolated chorea or indolent subclinical carditis the window for group A streptococcal infection is nine months (s 9(2)). Group C or G streptococcal pharyngeal infection carries a three month window (s 9(3)). Crowded living or working conditions and dental caries are assessed within one year (s 9(4)-(5)). These technical differences are material to causation findings.

4. The inability to obtain appropriate clinical management factor is constrained. Section 9(6) lists inability to obtain appropriate clinical management as a factor, but subsection 10(2) narrows its application to situations where the acute rheumatic fever was suffered or contracted before or during, but did not arise out of, the person’s relevant service. This means that the factor cannot be used to establish causation by service where the disease arose out of service. Practitioners must attend to that conditionality.

5. Nexus to relevant service is mandatory. Section 10(1) requires that any factor relied upon be related to the person’s relevant service as defined in Schedule 1. The Schedule lists specific service categories. Establishing that a factor existed is necessary but not sufficient; its relation to the person’s relevant service must be proved.

6. Cross‑SoP references can complicate proof. Section 11 requires that where a s 9 factor refers to an injury or disease covered by another SoP, that other SoP’s factors apply as in force. This can require contemporaneous application of multiple SoPs and careful matching of their respective factor lists, editions and amendments.

7. Death claims require contribution, not exclusive causation. Section 7(5) includes death from a terminal event or condition that was contributed to by the person’s acute rheumatic fever. Schedule 1 lists examples of terminal events. Therefore a death need not be solely caused by acute rheumatic fever, only that ARF contributed to the terminal event.

8. Repeal and commencement timing. The instrument repealed the 2011 SoP (s 4) and commenced on 27 May 2019 (s 2). For claims spanning these dates, practitioners must identify which instrument applies under the VEA/MRCA transitional or temporal rules; the SoP text itself does not set out transitional provisions.

9. No procedural detail in the SoP. The instrument does not prescribe how evidence must be presented, nor does it set evidentiary rules or procedural timelines. Those matters are determined by the VEA and MRCA processes. Failure to follow statutory procedural requirements could undermine a claim even where the SoP criteria are met.

10. Limited scope for non‑clinical factors. While the SoP accepts environmental and access factors such as crowded living or dental caries, the list in s 9 is finite. Factors outside that list will not, on their own, raise a reasonable hypothesis under this SoP.

In short, claimants and advisers must map the factual matrix precisely to the definitional and temporal structure of the SoP, assemble laboratory and clinical evidence that matches the definitions in s 7 and Note 2, and demonstrate the nexus to relevant service per s 10. Overlooking any of these technical elements can materially affect whether a reasonable hypothesis is found.

Compliance in this context means preparing and presenting a claim that meets the SoP’s criteria so that a reasonable hypothesis is raised connecting acute rheumatic fever or death from it to relevant service. The SoP supplies the causal and temporal checklist. The steps below distil what the instrument requires and the documents and proof that follow logically from its text.

1. Identify the claim context and applicable statutory provision. Confirm that the claim is one to which section 120A of the VEA or section 338 of the MRCA applies, because the SoP only applies to those claims (s 5). If a claim is outside those statutory points, the SoP will not be the controlling RMA instrument.

2. Establish the operative diagnosis in the terms of the SoP. The SoP’s diagnosis is not satisfied by a code alone. Show that acute rheumatic fever, as defined in s 7(2), is present. That requires demonstrating an inflammatory autoimmune disease following laboratory confirmed beta‑haemolytic streptococcal infection, and excluding post‑streptococcal reactive arthritis (s 7(2)(a)-(b)). Use clinical notes to document manifestations listed in Note 1 such as carditis, arthritis, chorea, or subclinical presentations.

3. Produce laboratory confirmation. For the definition in s 7(2) adherence to Note 2 is crucial. Collect throat culture results, rapid antigen test results, molecular assay results or serology that confirm streptococcal infection. Where only later serology is available, ensure it is linked in clinical records to the timing of clinical onset. Absent laboratory evidence it will be difficult to meet the textually stated definition.

4. Map the factor list and the applicable time window. Review s 9 and identify which factor or factors (at least one required) can be supported by the evidence. Note the timing requirements: three months for group A streptococcal infection of skin or pharynx (s 9(1)); nine months for isolated chorea or indolent subclinical carditis where group A is implicated (s 9(2)); three months for group C or G pharyngeal infection (s 9(3)); one year for crowded living or working conditions and for dental caries (s 9(4)-(5)). Assemble dated clinical, laboratory and environmental or dental records to demonstrate the relevant temporal link to clinical onset.

5. Demonstrate nexus to relevant service. For any factor relied upon, demonstrate how that factor is related to the person’s relevant service as defined in Schedule 1 (s 10(1) and Schedule 1). This will typically require: service records, deployment dates, postings and location evidence, contemporaneous medical attendances while on service, and narrative linking the occurrence of the factor to service circumstances. Where relying on s 9(6) inability to obtain appropriate clinical management, ensure the specific limitation in s 10(2) is addressed: the ARF must have been suffered or contracted before or during, but must not have arisen out of, the relevant service if this factor is to be used.

6. Where a factor refers to another SoP, follow that SoP. If any s 9 factor refers to an injury or disease already covered by a different SoP, obtain and apply the other SoP’s factors as they are in force (s 11). Practically this requires checking the current RMA SoP register for the operative instrument and matching its factors and definitions to the claimant’s evidence.

7. Prepare death claims to show contribution. If the claim concerns death, gather medical evidence to show that the person’s acute rheumatic fever contributed to the terminal event or condition identified in Schedule 1 (s 7(5) and Schedule 1). Collect hospital records, coroner’s findings if available, death certificates, and contemporaneous clinical notes that link ARF to the terminal event.

8. Use ICD‑10‑AM codes as adjuncts, not substitutes. While codes I00, I01 or I02 are associated with acute rheumatic fever (s 7(3)), use them to support, not to replace, the textual definition and laboratory evidence. If referring to codes, cite the edition specified in s 7(4) for consistency.

9. Maintain a paper trail of attempts to obtain care. If relying on inability to obtain appropriate clinical management, document dates, attempts to access care, referrals, wait times, refusals, or logistical barriers in the service context. Because s 10(2) narrows the application of s 9(6), confirm the chronology of ARF relative to service to establish that the disease was suffered or contracted before or during, but did not arise out of, the relevant service.

10. Anticipate cross‑checking by decision makers. Decision makers will assess whether at least one factor exists and whether it is related to relevant service. Ensure records are precise as to dates, locations and test results so the SoP’s temporal and nexus requirements can be evaluated directly under s 9 and s 10.

11. Prepare for multi‑disciplinary evidence. Where the clinical presentation is complex (for example isolated chorea, subclinical carditis, or mixed presentations), consider obtaining expert clinical opinions that map the clinical findings to the SoP definitions and time frames in s 7 and s 9.

12. Note the limits of the SoP. The SoP does not prescribe how to lodge a claim, appeal a decision, or present witnesses. Those procedural steps must comply with the VEA and MRCA frameworks. The SoP should be used as the causation checklist in assembling supporting materials for the statutory claim process.

Following these steps aligns claim preparation with the exact statutory text: the clinical definition in s 7, the factor list and time windows in s 9, the service nexus and limitation in s 10, cross‑SoP application in s 11, and the definitions in Schedule 1.